Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
DOGWOOD THERAPEUTICS INC (DWTX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.04+0.97%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for DWTX yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Raise capital through direct offering to fund operations | Capital raising supports ongoing development despite losses. | Improving | failure to raise sufficient capital to fund operations in 2026 | Qualitative: $5.0M raised (Oct 2026) DWTX entered a subscription agreement with Sealbond for 4.1M shares at $1.22, raising approximately $5.0M in a private placement. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 5, 2026
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative clinical-stage biotech, not a proven compounder: the company is loss-making, risk is high, and confidence in the evidence is low. The 1-to-3-year thesis is in a watch state, with Halneuron progress and new financing offset by pending clinical results and limited proof of commercial revenue.
The supplied evidence does not include a valuation or a clear account of market expectations, so whether DWTX is cheap or expensive versus peers cannot be assessed. The evidence does show that partnership potential is described as up to $100 million, but no revenue or partnership payment is reported, so that potential is not yet financial proof.
Near term, results may remain uneven: the company reported an operating loss, and the evidence flags elevated risk of a next-quarter earnings miss. Over the multi-year view, Halneuron enrollment and October financing support Phase 3 preparation, but the Phase 2b result and Phase 3 design are still pending; SP16 progress beyond authorization is also not demonstrated here.
The key swing factor is whether Halneuron produces a positive Phase 2b readout and can move toward Phase 3 with adequate funding. The thesis also depends on execution with SP16 and whether antiviral partnership potential turns into actual payments; weakening jobs data or guidance cuts would add near-term risk, while strength among Healthcare bellwethers is a sector tailwind.
For the next 1 to 3 years, DWTX remains a high-risk, evidence-limited clinical development story, with concrete enrollment and financing progress but major clinical and commercial milestones unresolved. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A supporting condition in DOGWOOD THERAPEUTICS INC's published investment case. The stated target is cash burn limited to about -$4.59 million. |
| Broken |
| cash burn worsens beyond -$4.59 million next quarter |
Cash from operations: $-3.611M FY2026-Q2; GAAP. Published target: cash burn limited to about -$4.59 million. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Jun 30, 2026-3,611,087 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Develop and commercialize legacy antiviral assets with potential value up to $100M | Dogwood aims to develop antiviral assets worth up to $100 million. | Improving | no partnership or commercialization progress realizing value toward $100M by end 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Manage operating expenses to reduce net losses | The company is managing expenses to reduce losses from -$15.81M to -$5.08M. | Broken | operating losses worsen beyond -$5.08 million next quarter | Operating income: $-14.064M FY2026-Q2; GAAP. Published target: operating income improved to about -$5.08 million. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 14, 2026-14,063,525 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.74 → $-0.72 · observed estimates
$0.02B → $0.02B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.74 | $18,730,000 | 2 / 3 |
| 2026-07-25 | $-0.74 | $18,730,000 | 2 / 3 |
| 2026-07-26 | $-0.74 | $18,730,000 | 2 / 3 |
| 2026-07-27 | $-0.74 | $18,730,000 | 2 / 3 |
| 2026-07-28 | $-0.74 | $18,730,000 | 2 / 3 |
| 2026-07-29 | $-0.74 | $18,730,000 | 2 / 3 |
| 2026-07-30 | $-0.74 | $18,730,000 | 2 / 3 |
| 2026-07-31 | $-0.65 | $0 | 3 / 3 |
| 2026-08-01 | $-0.74 | $18,730,000 | 2 / 3 |
| 2026-08-02 | $-0.65 | $0 | 3 / 3 |
| 2026-08-03 | $-0.65 | $0 | 3 / 3 |
| 2026-08-04 | $-0.65 | $0 | 3 / 3 |
| 2026-08-05 | $-0.65 | $0 | 3 / 3 |
| 2026-08-06 | $-0.74 | $18,730,000 | 2 / 3 |
| 2026-08-07 | $-0.74 | $18,730,000 | 2 / 3 |
| 2026-08-08 | $-0.65 | $0 | 3 / 3 |
| 2026-08-09 | $-0.65 | $0 | 3 / 3 |
| 2026-08-10 | $-0.74 | $18,730,000 | 2 / 3 |
| 2026-08-11 | $-0.65 | $0 | 3 / 3 |
| 2026-08-12 | $-0.65 | $0 | 3 / 3 |
| 2026-08-13 | $-0.74 | $18,730,000 | 2 / 3 |
| 2026-08-14 | $-0.74 | $18,730,000 | 2 / 3 |
| 2026-08-15 | $-0.74 | $18,730,000 | 2 / 3 |
| 2026-08-16 | $-0.74 | $18,730,000 | 2 / 3 |
| 2026-08-17 | $-0.74 | $18,730,000 | 2 / 3 |
| 2026-08-18 | $-0.74 | $18,730,000 | 2 / 3 |
| 2026-08-19 | $-0.74 | $18,730,000 | 2 / 3 |
| 2026-08-20 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-08-21 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-08-22 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-08-23 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-08-24 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-08-25 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-08-26 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-08-27 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-08-28 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-08-29 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-08-30 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-08-31 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-09-01 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-09-02 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-09-03 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-09-04 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-09-05 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-09-06 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-09-07 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-09-08 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-09-09 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-09-10 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-09-11 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-09-12 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-09-13 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-09-14 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-09-15 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-09-16 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-09-17 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-09-18 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-09-19 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-09-20 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-09-21 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-09-22 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-09-23 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-09-24 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-09-25 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-09-26 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-09-27 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-09-28 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-09-29 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-09-30 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-10-01 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-10-02 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-10-03 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-10-04 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-10-05 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-10-06 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-10-07 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-10-08 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-10-09 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-10-10 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-10-11 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-10-12 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-10-13 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-10-14 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-10-15 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-10-16 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-10-17 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-10-18 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-10-19 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-10-20 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-10-21 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-10-22 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-10-23 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-10-24 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-10-25 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-10-26 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-10-27 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-10-28 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-10-29 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-10-30 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-10-31 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-11-01 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-11-02 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-11-03 | $-0.72 | $18,730,000 | 2 / 3 |
| 2026-11-04 | $-0.72 | $18,730,000 | 2 / 3 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 2 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
3 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.